IntelliPharmaCeutics International Inc IPCIF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IPCIF is a good fit for your portfolio.
News
-
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
-
Intellipharmaceutics Announces Cease Trade Order
-
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
-
Intellipharmaceutics International Inc. Announces Stock Option Grant
Trading Information
- Previous Close Price
- $0.06
- Day Range
- $0.06–0.08
- 52-Week Range
- $0.00–0.14
- Bid/Ask
- $0.04 / $0.12
- Market Cap
- $1.99 Mil
- Volume/Avg
- 7,500 / 6,643
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.44
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 11
Valuation
|
Metric
|
IPCIF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.44 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IPCIF
|
|---|---|
Quick Ratio | 0.05 |
Current Ratio | 0.06 |
Interest Coverage | −8.88 |
Quick Ratio
IPCIF
Profitability
|
Metric
|
IPCIF
|
|---|---|
Return on Assets (Normalized) | −127.79% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
IPCIF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mhhfytdfy | Yxrmg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wfhrbhxsx | Rllscmf | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Glfxkpxzh | Hvpyj | $97.8 Bil | |
MRNA
| Moderna Inc | Bktbmjl | Gmjs | $38.8 Bil | |
ARGX
| argenx SE ADR | Yzfdtght | Lvt | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Lhcsyzdty | Zrl | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rcjrtxy | Xlvnwb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vcjlxqxw | Hwgtwxc | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Swhtsmcnj | Bhpxrgl | $12.5 Bil | |
INCY
| Incyte Corp | Svmcmdm | Ybdkwxm | $11.5 Bil |